Darolutamide in nmCRPCIr al contenidoOncologíaDarolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer Fizazi K, et al. N Engl J Med. 2019;380:1235–1246Contenido relacionadonmCRPC and Survival with DarolutamideCPRCnmOS and AEs with darolutamide vs apalutamide vs enzalutamideCPRCnmTreating the patient and not just the cancerCáncer de próstata
